根除幽门螺杆菌对冠心病患者长期服用小剂量阿司匹林所致消化道损害的影响

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the impact of Helicobacter pylori eradication therapy (Hp) and low dose Aspirin on upper digestive tract mucosal injury among patients with coronary heart disease, and to provide evidence for making clinical decision.Methods A total of 105 patients combined with coronary heart disease and Hp infection were selected from January 2014 to December 2015 in our hospital.The patients were divided into Hp group (n=52) and control group (n=53) by using random number table method.Hp group received anti-Hp treatment according to standard protocol, and control group received routine treatment.The patients were followed up for 6 months, the occurrence of gastrointestinal symptoms and upper gastrointestinal mucosal injury were observe between two groups.Results The occurrence of gastrointestinal symptoms in Hp group and control group was 19.2% and 49.1% respectively;the occurrence of upper gastrointestinal mucosal injury in Hp group and control group was 7.7% and 22.6% respectively.The total occurrence rates of gastrointestinal symptoms and upper gastrointestinal mucosal injury were lower in Hp group than those in the control group, the differences were statistically significant (P<0.05).Conclusion To reduce the risk of gastrointestinal symptoms and upper gastrointestinal mucosal injury, patients combined with coronary atherosclerosis and Hp infectious should eradicate Hp infections.

Key words： Coronary heart disease Aspirin Helicobacter pylori

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I20/40

[1]	孙宁玲.阿司匹林与心脑血管疾病一级预防：2011年新进展[J].中国实用内科杂志，2012，32（1）：79-80.
[2]	Bardou M，Barkun AN.Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs：from risk factor identification to risk factor intervention[J].Joint Bone Spine，2010，77（1）：6-12.
[3]	胡伏莲.幽门螺杆菌感染诊断指南[M].2版.北京：人民卫生出版社，2013：26-43.
[4]	王晶璠，盖亚男，孙永华.根除幽门螺杆菌预防长期服用小剂量阿司匹林患者上消化道粘膜损伤的临床研究[J].解放军医药杂志，2017，29（3）：69-72.
[5]	刘文忠，谢勇，成虹，等.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志，2012，51（6）：832-837.
[6]	Lanza FL，Graham DY，Davis RE，et al.Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury.effect of scoring method[J].Dig Dis Sci，1990，35（12）：1494-1499.
[7]	Sostres C，Lanas A.Gastrointestinal effects of aspirin[J].Nat Rev Gastroenterol Hepatol，2011，8（7）：385-394.
[8]	马玉真.冠心病患者抗血小板治疗致上消化道事件分析与对策[J].中国实用医药，2012，7（25）：91-92.
[11]	王又和.阿司匹林治疗冠心病患者合并上消化道出血的影响因素[J].世界华人消化杂志，2017，25（23）：2155-2160.
[9]	Iwamoto J，Saito Y，Honda A，et al.Clinical feature of gastroduodenal injury associated with long-term low dose aspirin therapy[J].World J Gastroenterol，2013，19（11）：1673-1682.
[10]	Cryer B，Bhatt DL，Lanza FL，et al.Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine：a randomized clinical trial[J].Am J Gastroenterol，2011，106（2）：272-277.
[12]	Sokic-Milutinovic A，Krstic M，Rozer-Smolovic B，et al.Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy：4 months follow-up study[J].Dig Dis Sci，2010，55（10）：2887-2892.
[13]	Bazzoli F，De Luca L，Graham DY.Helicobacter pylori infection and the use of NSAID[J].Best Paract Res Clin Gastroenterol，2001，15（5）：77-785.
[14]	Yeomans ND，Garas G，Hawkey CJ.Nonsteroidal anti-inflammatory drugs controcersy[J].Gastroenterol Clin North Am，2000，29（4）：791-805.
[15]	Schraier M，Petrelli L，Bonfanti M，et al.Experimental model of infection of Hilicobcter pylori in the mouse.a study of gastric damage caused by indomenthacin[J].Acta Gastroenterol Latinnoam，2001，31（3）：115-121.
[16]	Rybar I，Massaryk P，Mateicka F，et al.Nonsteroidal antiinflammatory drug induces mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori[J].Int J Clin Pharmacol Res，2001，21（3）：119-125.